BR112017004035A2 - inibidores macrocíclicos de rip2 quinase - Google Patents
inibidores macrocíclicos de rip2 quinaseInfo
- Publication number
- BR112017004035A2 BR112017004035A2 BR112017004035A BR112017004035A BR112017004035A2 BR 112017004035 A2 BR112017004035 A2 BR 112017004035A2 BR 112017004035 A BR112017004035 A BR 112017004035A BR 112017004035 A BR112017004035 A BR 112017004035A BR 112017004035 A2 BR112017004035 A2 BR 112017004035A2
- Authority
- BR
- Brazil
- Prior art keywords
- kinase inhibitors
- rip2 kinase
- macrocyclic
- compounds
- rip2
- Prior art date
Links
- 101150021296 rip2 gene Proteins 0.000 title abstract 3
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000002678 macrocyclic compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção refere-se a compostos macrocíclicos e composições contendo os referidos compostos que atuam como inibidores de quinases, especialmente como inibidores de rip2 e/ou seus mutantes, para uso no diagnóstico, na prevenção e/ou no tratamento de doenças associadas à rip2-quinase. além disso, a presente invenção provê métodos para utilizar os referidos compostos, por exemplo, como medicamento ou agente diagnóstico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185130 | 2014-09-17 | ||
| EP14185130.3 | 2014-09-17 | ||
| PCT/EP2015/071347 WO2016042087A1 (en) | 2014-09-17 | 2015-09-17 | Macrocyclic rip2 kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112017004035A2 true BR112017004035A2 (pt) | 2017-12-05 |
| BR112017004035A8 BR112017004035A8 (pt) | 2023-05-09 |
| BR112017004035B1 BR112017004035B1 (pt) | 2023-11-14 |
Family
ID=51687776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017004035-2A BR112017004035B1 (pt) | 2014-09-17 | 2015-09-17 | Inibidores macrocíclicos de rip2 quinase e composições farmacêuticas |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10676486B2 (pt) |
| EP (1) | EP3194407B1 (pt) |
| JP (1) | JP6736545B2 (pt) |
| KR (1) | KR102563829B1 (pt) |
| CN (1) | CN106687464B (pt) |
| AU (1) | AU2015316799B2 (pt) |
| BR (1) | BR112017004035B1 (pt) |
| CA (1) | CA2958782C (pt) |
| DK (1) | DK3194407T3 (pt) |
| EA (1) | EA032872B1 (pt) |
| ES (1) | ES2763344T3 (pt) |
| HR (1) | HRP20192334T1 (pt) |
| HU (1) | HUE048518T2 (pt) |
| IL (1) | IL250544B (pt) |
| LT (1) | LT3194407T (pt) |
| MX (1) | MX2017003469A (pt) |
| MY (1) | MY186523A (pt) |
| PL (1) | PL3194407T3 (pt) |
| PT (1) | PT3194407T (pt) |
| SA (1) | SA517381087B1 (pt) |
| SG (1) | SG11201701116XA (pt) |
| SI (1) | SI3194407T1 (pt) |
| TW (1) | TWI709563B (pt) |
| UA (1) | UA121315C2 (pt) |
| WO (1) | WO2016042087A1 (pt) |
| ZA (1) | ZA201701331B (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180088113A (ko) * | 2017-01-26 | 2018-08-03 | 한미약품 주식회사 | 이미다조피리다진 화합물 |
| US20230126352A1 (en) | 2020-01-31 | 2023-04-27 | Oncodesign Sa | Macrocyclic rip2-kinase inhibitors |
| WO2024051631A1 (zh) * | 2022-09-07 | 2024-03-14 | 苏州朗睿生物医药有限公司 | 一种大环咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| WO1995009615A1 (en) | 1993-10-01 | 1995-04-13 | Astra Aktiebolag | Process i |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| AU2007316417B2 (en) * | 2006-11-06 | 2013-08-22 | Tolero Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| AR077468A1 (es) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| KR102132405B1 (ko) * | 2010-05-20 | 2020-07-09 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| TWI547494B (zh) * | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| AU2012314035B2 (en) | 2011-09-30 | 2016-12-15 | Oncodesign S.A. | Macrocyclic LRRK2 kinase inhibitors |
| CN103930427B (zh) * | 2011-09-30 | 2016-03-09 | 昂科迪塞恩股份有限公司 | 大环flt3激酶抑制剂 |
-
2015
- 2015-09-17 EA EA201790609A patent/EA032872B1/ru unknown
- 2015-09-17 HU HUE15766800A patent/HUE048518T2/hu unknown
- 2015-09-17 TW TW104130751A patent/TWI709563B/zh active
- 2015-09-17 LT LTEP15766800.5T patent/LT3194407T/lt unknown
- 2015-09-17 PL PL15766800T patent/PL3194407T3/pl unknown
- 2015-09-17 JP JP2017514486A patent/JP6736545B2/ja active Active
- 2015-09-17 US US15/505,976 patent/US10676486B2/en active Active
- 2015-09-17 WO PCT/EP2015/071347 patent/WO2016042087A1/en active Application Filing
- 2015-09-17 MX MX2017003469A patent/MX2017003469A/es active IP Right Grant
- 2015-09-17 CN CN201580050163.3A patent/CN106687464B/zh active Active
- 2015-09-17 UA UAA201703558A patent/UA121315C2/uk unknown
- 2015-09-17 KR KR1020177010128A patent/KR102563829B1/ko active IP Right Grant
- 2015-09-17 EP EP15766800.5A patent/EP3194407B1/en active Active
- 2015-09-17 AU AU2015316799A patent/AU2015316799B2/en active Active
- 2015-09-17 SI SI201531050T patent/SI3194407T1/sl unknown
- 2015-09-17 MY MYPI2017700447A patent/MY186523A/en unknown
- 2015-09-17 BR BR112017004035-2A patent/BR112017004035B1/pt active IP Right Grant
- 2015-09-17 DK DK15766800.5T patent/DK3194407T3/da active
- 2015-09-17 ES ES15766800T patent/ES2763344T3/es active Active
- 2015-09-17 CA CA2958782A patent/CA2958782C/en active Active
- 2015-09-17 SG SG11201701116XA patent/SG11201701116XA/en unknown
- 2015-09-17 PT PT157668005T patent/PT3194407T/pt unknown
-
2017
- 2017-02-09 IL IL250544A patent/IL250544B/en active IP Right Grant
- 2017-02-22 ZA ZA2017/01331A patent/ZA201701331B/en unknown
- 2017-03-14 SA SA517381087A patent/SA517381087B1/ar unknown
-
2019
- 2019-12-27 HR HRP20192334TT patent/HRP20192334T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017011851A2 (es) | Compuestos novedosos | |
| BR112015022650A2 (pt) | inibidores de cinase induzível por sal macrocíclico | |
| BR112017018368A2 (pt) | composições contendo rna para o tratamento de doenças tumorais | |
| DOP2016000195A (es) | Compuestos | |
| BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
| BR112015029969A2 (pt) | tratamento de câncer usando moduladores de isoformas quinase pi3 | |
| BR112016005881A2 (pt) | composto, composição farmacêutica e uso do composto | |
| BR112016029334A2 (pt) | produto farmacêutico, uso de um anticorpo, kit, método para tratar um paciente com câncer e métodos e usos de novos produtos | |
| BR112015022982A2 (pt) | inibidores macrocíclicos de rip2 quinase | |
| BR112017003433A2 (pt) | inibidores espirocíclicos de catepsina c | |
| UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
| BR112017007144A2 (pt) | ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição. | |
| BR112017004153A2 (pt) | métodos para tratamento de infecções por protozoários | |
| BR112016004358A8 (pt) | combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| CL2015000615A1 (es) | Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau. | |
| BR112017005299A2 (pt) | inibidores de lrrk2 cinase macrocíclicos | |
| BR112015017241A8 (pt) | composto, composição farmacêutica, uso do composto e da composição farmacêutica e kit | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| ECSP16008797A (es) | Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos | |
| BR112015027440A2 (pt) | DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO | |
| BR112016026545A8 (pt) | eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama | |
| BR112017002675A2 (pt) | métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila | |
| BR112016015997A2 (pt) | ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas? | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: ONCODESIGN PRECISION MEDICINE (OPM) (FR) |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/09/2015, OBSERVADAS AS CONDICOES LEGAIS |